Skip to main content

Table 2 Changes in the BCVA and CRT from baseline after IVR treatment in all AMD, tAMD and PCV patients

From: Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up

  1 Month P value* 3 Months P value* 6 Months P value* 12 Months P value*
Change in BCVA Mean Median (IQR)   Mean Median (IQR)   Mean Median (IQR)   Mean Median (IQR)  
total −0.03 0.00 (-0.12 - 0.00) 0.12 −0.11 −0.12 ( -0.24 - 0.00) <0.001 −0.10 −0.12 ( -0.24 - 0.00) 0.001 −0.09 −0.12 (-0.30 - 0.00) 0.02
tAMD −0.06 0.00 (-0.17 - 0.00) 0.01 −0.17 −0.20 (-0.30 - -0.05) <0.001 −0.15 −0.18 (-0.30 - -0.05) 0.006 −0.16 −0.18 (-0.30 - -0.05) 0.01
PCV 0.00 0.00 (-0.10 - 0.00) 0.73 −0.06 −0.07(-0.22 - 0.00) 0.08 −0.06 −0.04 (-0.18 - 0.00) 0.08 −0.04 −0.05 (-0.24 - 0.10) 0.33
Change in CRT Mean Median (IQR)   Mean Median (IQR)   Mean Median (IQR)   Mean Median (IQR)  
total −104 −74 (-142 - -25) < 0.001 −132 −119 (-170 - -47) < 0.001 −95 −53 (-126 - -28) < 0.001 −94 −80 (-140 - -40) < 0.001
tAMD −112 −72 (-147 - -29) < 0.001 −144 −93 (-191 - -72) < 0.001 −120 −52 (-154 - -32) < 0.001 −137 −97 (-197 - -52) < 0.001
PCV −98 −107 (-142 - -25) < 0.001 −121 −128 (-170 - -45) < 0.001 −74 −55 (-119 - -28) < 0.001 −94 −71 (-133 - -33) < 0.001
  1. BCVA, Best corrected visual acuity (LogMAR); CRT, Central retinal thickness; IQR, Interquartile range.
  2. *Wilcoxon signed rank test (comparison with baseline).